Distinct subjects for predicate <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence> sorted by frequency

ResourceCount
ziprasidone_maximum_concentration_continuous_value6
aripiprazole_maximum_concentration_continuous_value5
paroxetine_inhibits_cyp2d65
perphenazine_substrate_of_cyp2d65
14-hydroxyclarithromycin_maximum_concentration_continuous_value4
atorvastatin_maximum_concentration_continuous_value4
clarithromycin_maximum_concentration_continuous_value4
clozapine_maximum_concentration_continuous_value4
diltiazem_bioavailability_continuous_value4
ketoconazole_inhibits_cyp3a44
ziprasidone_substrate_of_cyp3a44
O-desmethylvenlafaxine_maximum_concentration_continuous_value3
alprazolam_primary_total_clearance_mechanism_Metabolic_Clearance3
alprazolam_substrate_of_cyp3a43
atorvastatin_has_metabolite_ortho-hydroxy-atorvastatin3
atorvastatin_has_metabolite_para-hydroxy-atorvastatin3
atorvastatin_substrate_of_cyp3a43
bupropion_maximum_concentration_continuous_value3
chlorpromazine_maximum_concentration_continuous_value3
cimetidine_increases_auc_imipramine3
cinacalcet_inhibits_cyp2d63
citalopram_does_not_inhibit_cyp3a43
clarithromycin_inhibition_constant_cyp3a43
clarithromycin_inhibits_cyp3a43
cyp2d6_controls_formation_of_O-desmethylvenlafaxine3
cyp3a4_controls_formation_of_4-(4-chlorophenyl)-4-hydroxypiperidine3
diltiazem_inhibition_constant_cyp3a43
duloxetine_inhibits_cyp2d63
erythromycin_inhibition_constant_cyp3a43
fluconazole_increases_auc_midazolam3
fluconazole_inhibits_cyp3a43
fluoxetine_inhibits_cyp2d63
fluvastatin_maximum_concentration_continuous_value3
fluvoxamine_inhibits_cyp1a23
indinavir_inhibits_cyp3a43
metronidazole_maximum_concentration_continuous_value3
mexiletine_inhibits_cyp1a23
nefazodone_increases_auc_alprazolam3
nefazodone_inhibits_cyp3a43
paroxetine_increases_auc_desipramine3
quetiapine_substrate_of_cyp3a43
ritonavir_inhibits_cyp3a43
sertraline_increases_auc_desipramine3
sertraline_inhibits_cyp2d63
simvastatin_substrate_of_cyp3a43
telithromycin_inhibits_cyp3a43
venlafaxine_does_not_inhibit_cyp1a23
venlafaxine_has_metabolite_O-desmethylvenlafaxine3
venlafaxine_maximum_concentration_continuous_value3
venlafaxine_substrate_of_cyp2d63
alprazolam_bioavailability_continuous_value2
alprazolam_has_metabolite_4-hydroxyalprazolam2
alprazolam_has_metabolite_alpha-hydroxyalprazolam2
alprazolam_maximum_concentration_continuous_value2
alprazolam_primary_metabolic_clearance_enzyme_cyp3a42
alprazolam_substrate_of_cyp3a52
amiodarone_inhibits_cyp2c92
amiodarone_inhibits_cyp2d62
aripiprazole_substrate_of_cyp3a42
atazanavir_inhibits_cyp3a42
atazanavir_inhibits_cyp3a52
atomoxetine_does_not_inhibit_cyp2d62
atomoxetine_primary_total_clearance_enzyme_cyp2d62
atorvastatin_primary_total_clearance_mechanism_Metabolic_Clearance2
atorvastatin_substrate_of_cyp3a52
beta-hydroxy-lovastatin_substrate_of_cyp3a42
beta-hydroxy-simvastatin_substrate_of_cyp3a42
bupropion_inhibits_cyp2d62
celecoxib_inhibits_cyp2d62
cimetidine_increases_auc_amitriptyline2
cimetidine_increases_auc_venlafaxine2
cinacalcet_does_not_inhibit_cyp3a42
cinacalcet_substrate_of_cyp3a42
ciprofloxacin_inhibits_cyp1a22
citalopram_does_not_inhibit_cyp2c92
clarithromycin_has_metabolite_14-hydroxyclarithromycin2
clarithromycin_increases_auc_atorvastatin2
clarithromycin_increases_auc_midazolam2
clarithromycin_inhibits_cyp3a52
clarithromycin_substrate_of_cyp3a42
clozapine_substrate_of_cyp1a22
clozapine_substrate_of_cyp2d62
clozapine_substrate_of_cyp3a42
cyp1a2_controls_formation_of_N-dealkylperphenazine2
cyp2b6_controls_formation_of_hydroxybupropion2
cyp2d6_controls_formation_of_N-dealkylperphenazine2
cyp3a4_controls_formation_of_14-hydroxyclarithromycin2
cyp3a4_controls_formation_of_N-dealkylperphenazine2
cyp3a4_controls_formation_of_N-desmethylvenlafaxine2
dehydro-aripiprazole_substrate_of_cyp3a42
desvenlafaxine_increases_auc_desipramine2
diltiazem_maximum_concentration_continuous_value2
duloxetine_substrate_of_cyp2d62
erythromycin_inhibits_cyp3a42
escitalopram_does_not_inhibit_cyp2c192
escitalopram_does_not_inhibit_cyp2c92
escitalopram_does_not_inhibit_cyp2d62
escitalopram_substrate_of_cyp2c192
eszopiclone_substrate_of_cyp3a42
fluconazole_inhibits_cyp2c92
fluoxetine_increases_auc_desipramine2
fluoxetine_substrate_of_cyp2d62
fluphenazine_maximum_concentration_continuous_value2
fluvoxamine_increases_auc_duloxetine2
fluvoxamine_increases_auc_lansoprazole2
fluvoxamine_inhibition_constant_cyp1a22
fluvoxamine_inhibits_cyp2c192
fluvoxamine_substrate_of_cyp2d62
hydroxybupropion_maximum_concentration_continuous_value2
iloperidone_substrate_of_cyp2d62
itraconazole_increases_auc_triazolam2
ketoconazole_increases_auc_alprazolam2
ketoconazole_increases_auc_triazolam2
ketoconazole_primary_total_clearance_mechanism_Metabolic_Clearance2
lovastatin_substrate_of_cyp3a42
mirtazapine_substrate_of_cyp1a22
mirtazapine_substrate_of_cyp2d62
mirtazapine_substrate_of_cyp3a42
montelukast_does_not_inhibit_cyp1a22
montelukast_does_not_inhibit_cyp2c92
nefazodone_increases_auc_triazolam2
nefazodone_is_not_substrate_of_cyp2d62
paliperidone_does_not_inhibit_cyp1a22
paliperidone_does_not_inhibit_cyp2a62
paliperidone_does_not_inhibit_cyp2c92
paroxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d62
paroxetine_increases_auc_duloxetine2
perphenazine_substrate_of_cyp1a22
perphenazine_substrate_of_cyp3a42
rabeprazole_substrate_of_cyp3a42
reduced-haloperidol_substrate_of_cyp3a42
risperidone_bioavailability_continuous_value2
risperidone_has_metabolite_9-hydroxyrisperidone2
risperidone_inhibition_constant_cyp2d62
risperidone_substrate_of_cyp2d62
ritonavir_inhibits_cyp2d62
rosuvastatin_bioavailability_continuous_value2
terbinafine_inhibits_cyp2d62
thioridazine_has_metabolite_mesoridazine2
thioridazine_substrate_of_cyp2d62
topiramate_does_not_inhibit_cyp1a22
topiramate_does_not_inhibit_cyp2a62
topiramate_does_not_inhibit_cyp2c92
topiramate_does_not_inhibit_cyp2e12
topiramate_does_not_inhibit_cyp3a42
trazodone_bioavailability_continuous_value2
venlafaxine_does_not_inhibit_cyp2c92
venlafaxine_does_not_inhibit_cyp3a42
venlafaxine_has_metabolite_N-desmethylvenlafaxine2
voriconazole_maximum_concentration_continuous_value2
zafirlukast_inhibits_cyp2c92
ziprasidone_does_not_inhibit_cyp1a22
ziprasidone_does_not_inhibit_cyp2c192
ziprasidone_does_not_inhibit_cyp2c92
ziprasidone_does_not_inhibit_cyp2d62
ziprasidone_has_metabolite_ziprasidone-sulphoxide2
ziprasidone_is_not_substrate_of_cyp1a22
zolpidem_substrate_of_cyp3a42
1-methylxanthine_has_metabolite_1-methyluric-acid1
7-ethoxyresorufin_in_vitro_probe_substrate_of_enzyme_cyp1a21
7-hydroxyperphenazine_maximum_concentration_continuous_value1
9-hydroxyrisperidone_inhibition_constant_cyp2d61
9-hydroxyrisperidone_primary_total_clearance_mechanism_Renal_Excretion1
N-demethyldesacetyl-diltiazem_primary_total_clearance_enzyme_cyp2d61
N-demethyldesacetyl-diltiazem_substrate_of_cyp2d61
N-desalkylquetiapine_does_not_inhibit_cyp1a21
N-desalkylquetiapine_does_not_inhibit_cyp2c191
N-desalkylquetiapine_does_not_inhibit_cyp2c91
N-desalkylquetiapine_does_not_inhibit_cyp2d61
N-desalkylquetiapine_does_not_inhibit_cyp3a41
N-desalkylquetiapine_substrate_of_cyp3a41
R-citalopram_does_not_inhibit_cyp1a21
R-citalopram_does_not_inhibit_cyp2c191
R-citalopram_does_not_inhibit_cyp2c91
R-citalopram_does_not_inhibit_cyp2d61
R-citalopram_substrate_of_cyp2c191
R-citalopram_substrate_of_cyp2d61
R-citalopram_substrate_of_cyp3a41
R-demethylcitalopram_does_not_inhibit_cyp1a21
R-demethylcitalopram_does_not_inhibit_cyp2c191
R-demethylcitalopram_does_not_inhibit_cyp2c91
R-demethylcitalopram_maximum_concentration_continuous_value1
R-demethylcitalopram_substrate_of_cyp2d61
R-didemethylcitalopram_does_not_inhibit_cyp1a21
R-didemethylcitalopram_does_not_inhibit_cyp2d61
R-didemethylcitalopram_maximum_concentration_continuous_value1
S-demethylcitalopram_does_not_inhibit_cyp1a21
S-demethylcitalopram_does_not_inhibit_cyp2c191
S-demethylcitalopram_does_not_inhibit_cyp2c91
S-demethylcitalopram_maximum_concentration_continuous_value1
S-demethylcitalopram_substrate_of_cyp2d61
S-didemethylcitalopram_does_not_inhibit_cyp1a21
S-didemethylcitalopram_does_not_inhibit_cyp2d61
S-didemethylcitalopram_maximum_concentration_continuous_value1
S-mephenytoin_in_vitro_probe_substrate_of_enzyme_cyp2c191
S-warfarin_in_vitro_probe_substrate_of_enzyme_cyp2c91
S-warfarin_primary_total_clearance_enzyme_cyp2c91
alpha-naphthoflavone_in_vitro_selective_inhibitor_of_enzyme_cyp1a21
alprazolam_is_not_substrate_of_cyp1a21
amiodarone_inhibits_cyp1a21
amiodarone_inhibits_cyp3a41
aripiprazole_bioavailability_continuous_value1
aripiprazole_does_not_inhibit_cyp1a21
aripiprazole_does_not_inhibit_cyp2c191
aripiprazole_does_not_inhibit_cyp2c91
aripiprazole_does_not_inhibit_cyp2d61
aripiprazole_does_not_inhibit_cyp3a41
aripiprazole_has_metabolite_dehydro-aripiprazole1
aripiprazole_increases_auc_escitalopram1
aripiprazole_increases_auc_venlafaxine1
aripiprazole_is_not_substrate_of_cyp1a11
aripiprazole_is_not_substrate_of_cyp1a21
aripiprazole_is_not_substrate_of_cyp2a61
aripiprazole_is_not_substrate_of_cyp2b61
aripiprazole_is_not_substrate_of_cyp2c191
aripiprazole_is_not_substrate_of_cyp2c81
aripiprazole_is_not_substrate_of_cyp2c91
aripiprazole_is_not_substrate_of_cyp2e11
aripiprazole_primary_total_clearance_mechanism_Metabolic_Clearance1
aripiprazole_substrate_of_cyp2d61
asenapine_is_not_substrate_of_cyp2d61
asenapine_maximum_concentration_continuous_value1
asenapine_primary_total_clearance_mechanism_Metabolic_Clearance1
atazanavir_does_not_inhibit_cyp1a21
atazanavir_does_not_inhibit_cyp2a61
atazanavir_does_not_inhibit_cyp2b61
atazanavir_does_not_inhibit_cyp2c191
atazanavir_does_not_inhibit_cyp2c91
atazanavir_does_not_inhibit_cyp2d61
atazanavir_does_not_inhibit_cyp2e11
atomoxetine_bioavailability_continuous_value1
atomoxetine_does_not_inhibit_cyp1a21
atomoxetine_does_not_inhibit_cyp2c91
atomoxetine_has_metabolite_4-hydroxyatomoxetine1
atomoxetine_has_metabolite_N-desmethylatomoxetine1
atomoxetine_primary_total_clearance_mechanism_Metabolic_Clearance1
atorvastatin_bioavailability_continuous_value1
atorvastatin_inhibition_constant_cyp2c81
atorvastatin_inhibits_cyp3a41
atorvastatin_is_not_substrate_of_cyp1a11
atorvastatin_is_not_substrate_of_cyp2b61
atorvastatin_is_not_substrate_of_cyp2c191
atorvastatin_is_not_substrate_of_cyp2c91
atorvastatin_is_not_substrate_of_cyp2d61
atorvastatin_is_not_substrate_of_cyp2e11
atorvastatin_primary_total_clearance_enzyme_cyp3a41
beta-hydroxy-lovastatin_has_metabolite_6'-exomethylene-lovastatin1
beta-hydroxy-lovastatin_has_metabolite_6'beta-hydroxy-lovastatin1
beta-hydroxy-lovastatin_inhibition_constant_cyp2c81
beta-hydroxy-lovastatin_maximum_concentration_continuous_value1
beta-hydroxy-lovastatin_primary_total_clearance_enzyme_cyp3a41
beta-hydroxy-simvastatin_does_not_inhibit_cyp3a41
beta-hydroxy-simvastatin_has_metabolite_6'-exomethylene-simvastatin1
beta-hydroxy-simvastatin_has_metabolite_6'-hydroxy-simvastatin1
beta-hydroxy-simvastatin_has_metabolite_6'-hydroxymethyl-simvastatin1
beta-hydroxy-simvastatin_inhibition_constant_cyp2c81
beta-hydroxy-simvastatin_primary_total_clearance_enzyme_cyp3a41
bufuralol_in_vitro_probe_substrate_of_enzyme_cyp2d61
bupropion_has_metabolite_erythrohydrobupropion1
bupropion_has_metabolite_hydroxybupropion1
bupropion_has_metabolite_threohydrobupropion1
bupropion_increases_auc_desipramine1
bupropion_primary_total_clearance_mechanism_Metabolic_Clearance1
bupropion_substrate_of_cyp2b61
caffeine_primary_total_clearance_enzyme_cyp1a21
celecoxib_does_not_inhibit_cyp2c191
celecoxib_does_not_inhibit_cyp2c91
celecoxib_does_not_inhibit_cyp3a41
celecoxib_maximum_concentration_continuous_value1
celecoxib_primary_total_clearance_mechanism_Metabolic_Clearance1
celecoxib_substrate_of_cyp2c91
chlorpromazine_bioavailability_continuous_value1
chlorpromazine_does_not_inhibit_cyp2c191
chlorzoxazone_in_vitro_probe_substrate_of_enzyme_cyp2e11
cimetidine_increases_auc_citalopram1
cimetidine_increases_auc_doxepin1
cimetidine_increases_auc_erythrohydrobupropion1
cimetidine_increases_auc_escitalopram1
cimetidine_increases_auc_mirtazapine1
cimetidine_increases_auc_paroxetine1
cimetidine_increases_auc_quetiapine1
cimetidine_increases_auc_sertraline1
cimetidine_increases_auc_theophylline1
cimetidine_increases_auc_threohydrobupropion1
cimetidine_increases_auc_ziprasidone1
cimetidine_inhibits_cyp1a21
cimetidine_inhibits_cyp3a41
cimetidine_inhibits_cyp3a51
cinacalcet_does_not_inhibit_cyp1a21
cinacalcet_does_not_inhibit_cyp2c191
cinacalcet_does_not_inhibit_cyp2c91
cinacalcet_does_not_inhibit_cyp3a51
cinacalcet_has_metabolite_hydrocinnamic-acid1
cinacalcet_has_metabolite_hydroxy-hydrocinnamic-acid1
cinacalcet_primary_total_clearance_mechanism_Metabolic_Clearance1
cinacalcet_substrate_of_cyp1a21
cinacalcet_substrate_of_cyp2d61
citalopram_bioavailability_continuous_value1
citalopram_does_not_inhibit_cyp2e11
citalopram_has_metabolite_demethylcitalopram1
citalopram_has_metabolite_didemethylcitalopram1
citalopram_increases_auc_desipramine1
citalopram_is_not_substrate_of_cyp3a41
citalopram_primary_total_clearance_mechanism_Metabolic_Clearance1
citalopram_substrate_of_cyp2c191
citalopram_substrate_of_cyp3a41
clarithromycin_bioavailability_continuous_value1
clarithromycin_fraction_absorbed_continuous_value1
clarithromycin_in_viVo_selective_inhibitor_of_enzyme_cyp3a41
clarithromycin_increases_auc_lansoprazole1
clarithromycin_increases_auc_pravastatin1
clarithromycin_increases_auc_trazodone1
clarithromycin_increases_auc_triazolam1
clarithromycin_is_not_substrate_of_cyp1a21
clarithromycin_is_not_substrate_of_cyp2c91
clarithromycin_is_not_substrate_of_cyp2d61
clopidogrel_increases_auc_bupropion1
clopidogrel_inhibition_constant_cyp2b61
clozapine-N-oxide_is_not_substrate_of_cyp2d61
clozapine_does_not_inhibit_cyp2c191
clozapine_has_metabolite_7-hydroxyclozapine1
clozapine_has_metabolite_clozapine-N-oxide1
clozapine_has_metabolite_desmethylclozapine1
clozapine_inhibition_constant_cyp2c191
clozapine_inhibition_constant_cyp2c91
clozapine_inhibition_constant_cyp2d61
clozapine_inhibition_constant_cyp3a41
clozapine_primary_total_clearance_mechanism_Metabolic_Clearance1
coumarin_in_vitro_probe_substrate_of_enzyme_cyp2a61
cyp1a2_controls_formation_of_3-methylxanthine1
cyp2c19_controls_formation_of_N-dealkylperphenazine1
cyp2c19_controls_formation_of_N-desmethylatomoxetine1
cyp2c19_controls_formation_of_N-desmethylsertraline1
cyp2c8_controls_formation_of_6alpha-hydroxy-paclitaxel1
cyp2c8_controls_formation_of_N-dealkylperphenazine1
cyp2c9_controls_formation_of_N-dealkylperphenazine1
cyp2c9_controls_formation_of_N-desmethylrosuvastatin1
cyp2d6_controls_formation_of_4-hydroxyatomoxetine1
cyp2d6_controls_formation_of_4-hydroxydebrisoquine1
cyp2d6_controls_formation_of_9-hydroxyrisperidone1
cyp2e1_controls_formation_of_1,3-dimethyluric-acid1
cyp3a4_controls_formation_of_1'-hydroxymidazolam1
cyp3a4_controls_formation_of_1,3-dimethyluric-acid1
cyp3a4_controls_formation_of_4-hydroxyalprazolam1
cyp3a4_controls_formation_of_4-hydroxymidazolam1
cyp3a4_controls_formation_of_6'beta-hydroxy-lovastatin1
cyp3a4_controls_formation_of_N-desmethyltamoxifen1
cyp3a4_controls_formation_of_alpha-hydroxyalprazolam1
cyp3a4_controls_formation_of_desmethylcitalopram1
cyp3a4_controls_formation_of_ortho-hydroxy-atorvastatin1
cyp3a4_controls_formation_of_para-hydroxy-atorvastatin1
cyp3a4_controls_formation_of_ziprasidone-sulphoxide1
cyp3a5_controls_formation_of_1'-hydroxymidazolam1
cyp3a5_controls_formation_of_4-hydroxyalprazolam1
cyp3a5_controls_formation_of_4-hydroxymidazolam1
cyp3a5_controls_formation_of_alpha-hydroxyalprazolam1
cyp3a5_controls_formation_of_ortho-hydroxy-atorvastatin1
cyp3a5_controls_formation_of_para-hydroxy-atorvastatin1
debrisoquine_in_vitro_probe_substrate_of_enzyme_cyp2d61
dehydro-aripiprazole_does_not_inhibit_cyp1a21
demethylcitalopram_does_not_inhibit_cyp3a41
demethylcitalopram_is_not_substrate_of_cyp2c191
demethylcitalopram_is_not_substrate_of_cyp3a41
desacetyldiltiazem_primary_total_clearance_enzyme_cyp2d61
desacetyldiltiazem_substrate_of_cyp2d61
desglymidodrine_primary_total_clearance_mechanism_Renal_Excretion1
desipramine_primary_total_clearance_enzyme_cyp2d61
desvenlafaxine_is_not_substrate_of_cyp2d61
dextromethorphan_in_viVo_probe_substrate_of_enzyme_cyp2d61
dextromethorphan_in_vitro_probe_substrate_of_enzyme_cyp2d61
dextromethorphan_primary_total_clearance_enzyme_cyp2d61
diltiazem_has_metabolite_N-demethyldesacetyl-diltiazem1
diltiazem_has_metabolite_N-demethyldiltiazem1
diltiazem_has_metabolite_desacetyldiltiazem1
diltiazem_increases_auc_beta-hydroxy-lovastatin1
diltiazem_increases_auc_imipramine1
diltiazem_increases_auc_midazolam1
diltiazem_increases_auc_simvastatin1
diltiazem_increases_auc_triazolam1
diltiazem_inhibits_cyp3a41
diltiazem_permanently_deactivates_catalytic_function_cyp3a41
diltiazem_primary_total_clearance_mechanism_Metabolic_Clearance1
diltiazem_substrate_of_cyp3a41
diltiazem_substrate_of_cyp3a51
diphenhydramine_increases_auc_venlafaxine1
duloxetine_does_not_inhibit_cyp2c191
duloxetine_does_not_inhibit_cyp2c91
duloxetine_does_not_inhibit_cyp3a41
duloxetine_does_not_inhibit_cyp3a51
duloxetine_increases_auc_theophylline1
duloxetine_primary_total_clearance_mechanism_Metabolic_Clearance1
duloxetine_substrate_of_cyp1a21
erythrohydrobupropion_maximum_concentration_continuous_value1
erythromycin_in_vitro_probe_substrate_of_enzyme_cyp3a41
erythromycin_increases_auc_alprazolam1
erythromycin_increases_auc_atorvastatin1
erythromycin_increases_auc_beta-hydroxy-simvastatin1
erythromycin_increases_auc_midazolam1
erythromycin_increases_auc_quetiapine1
erythromycin_increases_auc_simvastatin1
erythromycin_increases_auc_triazolam1
escitalopram_bioavailability_continuous_value1
escitalopram_does_not_inhibit_cyp1a21
escitalopram_does_not_inhibit_cyp2e11
escitalopram_has_metabolite_S-demethylcitalopram1
escitalopram_has_metabolite_S-didemethylcitalopram1
escitalopram_inhibits_cyp2d61
escitalopram_maximum_concentration_continuous_value1
escitalopram_primary_total_clearance_mechanism_Metabolic_Clearance1
escitalopram_substrate_of_cyp2d61
escitalopram_substrate_of_cyp3a41
eszopiclone_does_not_inhibit_CYP1A21
eszopiclone_does_not_inhibit_CYP2A61
eszopiclone_does_not_inhibit_CYP2C191
eszopiclone_does_not_inhibit_CYP2C91
eszopiclone_does_not_inhibit_CYP2D61
eszopiclone_does_not_inhibit_CYP2E11
eszopiclone_does_not_inhibit_CYP3A41
eszopiclone_has_metabolite_S-N-desmethylzopiclone1
eszopiclone_has_metabolite_S-zopiclone-N-oxide1
fluconazole_bioavailability_continuous_value1
fluconazole_increases_auc_fluvastatin1
fluconazole_increases_auc_triazolam1
fluconazole_inhibition_constant_cyp3a41
fluconazole_inhibits_cyp3a51
fluconazole_maximum_concentration_continuous_value1
fluconazole_primary_total_clearance_mechanism_Renal_Excretion1
fluoxetine_has_metabolite_norfluoxetine1
fluoxetine_in_viVo_selective_inhibitor_of_enzyme_cyp2d61
fluoxetine_increases_auc_alprazolam1
fluoxetine_increases_auc_imipramine1
fluoxetine_increases_auc_olanzapine1
fluoxetine_increases_auc_propafenone1
fluoxetine_inhibition_constant_cyp3a41
fluoxetine_maximum_concentration_continuous_value1
fluoxetine_primary_total_clearance_mechanism_Metabolic_Clearance1
fluphenazine_bioavailability_continuous_value1
fluphenazine_does_not_inhibit_cyp2c191
fluphenazine_inhibition_constant_cyp1a21
fluphenazine_inhibition_constant_cyp2d61
fluvastatin_bioavailability_continuous_value1
fluvastatin_inhibition_constant_cyp2c81
fluvastatin_primary_total_clearance_enzyme_cyp2c91
fluvastatin_primary_total_clearance_mechanism_Metabolic_Clearance1
fluvastatin_substrate_of_cyp2c81
fluvastatin_substrate_of_cyp2c91
fluvastatin_substrate_of_cyp3a41
fluvoxamine_bioavailability_continuous_value1
fluvoxamine_increases_auc_clozapine1
fluvoxamine_increases_auc_mexiletine1
fluvoxamine_increases_auc_omeprazole1
fluvoxamine_increases_auc_quinidine1
fluvoxamine_increases_auc_theophylline1
fluvoxamine_increases_auc_thioridazine1
fluvoxamine_increases_auc_tolbutamide1
fluvoxamine_inhibits_cyp2c91
fluvoxamine_primary_total_clearance_mechanism_Metabolic_Clearance1
furafylline_in_vitro_selective_inhibitor_of_enzyme_cyp1a21
gemfibrozil_inhibits_cyp2c81
haloperidol_does_not_inhibit_cyp2c191
haloperidol_has_metabolite_4-(4-chlorophenyl)-4-hydroxypiperidine1
haloperidol_has_metabolite_reduced-haloperidol1
haloperidol_inhibition_constant_cyp2d61
haloperidol_substrate_of_cyp3a41
hydroxybupropion_primary_total_clearance_mechanism_Renal_Excretion1
iloperidone_inhibits_cyp2d61
iloperidone_is_not_substrate_of_cyp1a11
iloperidone_is_not_substrate_of_cyp1a21
iloperidone_is_not_substrate_of_cyp2a61
iloperidone_is_not_substrate_of_cyp2b61
iloperidone_is_not_substrate_of_cyp2c191
iloperidone_is_not_substrate_of_cyp2c81
iloperidone_is_not_substrate_of_cyp2c91
iloperidone_is_not_substrate_of_cyp2e11
iloperidone_substrate_of_cyp3a41
indinavir_does_not_inhibit_cyp1a21
indinavir_does_not_inhibit_cyp2b61
indinavir_does_not_inhibit_cyp2c91
indinavir_does_not_inhibit_cyp2e11
indinavir_inhibits_cyp3a51
indomethacin_bioavailability_continuous_value1
indomethacin_primary_total_clearance_mechanism_Metabolic_Clearance1
itraconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a41
itraconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a41
itraconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a51
itraconazole_increases_auc_3alpha-hydroxypravastatin1
itraconazole_increases_auc_alprazolam1
itraconazole_increases_auc_atorvastatin1
itraconazole_increases_auc_beta-hydroxy-lovastatin1
itraconazole_increases_auc_lovastatin1
itraconazole_increases_auc_midazolam1
itraconazole_increases_auc_pravastatin1
itraconazole_increases_auc_rosuvastatin1
itraconazole_increases_auc_zolpidem1
itraconazole_inhibition_constant_cyp3a41
itraconazole_inhibits_cyp3a41
ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a41
ketoconazole_in_vitro_selective_inhibitor_of_enzyme_cyp3a41
ketoconazole_increases_auc_O-desmethylvenlafaxine1
ketoconazole_increases_auc_amitriptyline1
ketoconazole_increases_auc_desvenlafaxine1
ketoconazole_increases_auc_imipramine1
ketoconazole_increases_auc_midazolam1
ketoconazole_increases_auc_simvastatin1
ketoconazole_increases_auc_venlafaxine1
ketoconazole_increases_auc_zolpidem1
ketoconazole_inhibition_constant_cyp3a41
ketoconazole_maximum_concentration_continuous_value1
lansoprazole_bioavailability_continuous_value1
lansoprazole_does_not_inhibit_cyp2d61
lansoprazole_does_not_inhibit_cyp3a41
lansoprazole_increases_auc_lansoprazole1
lansoprazole_maximum_concentration_continuous_value1
lansoprazole_primary_total_clearance_enzyme_cyp2c191
lansoprazole_primary_total_clearance_mechanism_Metabolic_Clearance1
lansoprazole_substrate_of_cyp2c191
lansoprazole_substrate_of_cyp3a41
lansoprazole_substrate_of_cyp3a51
leflunomide_has_metabolite_teriflunomide1
lovastatin_bioavailability_continuous_value1
lovastatin_first_pass_effect_continuous_value1
lovastatin_has_metabolite_beta-hydroxy-lovastatin1
lovastatin_inhibition_constant_cyp2c81
lovastatin_maximum_concentration_continuous_value1
lovastatin_primary_total_clearance_enzyme_cyp3a41
lovastatin_primary_total_clearance_mechanism_Metabolic_Clearance1
mephenytoin_in_viVo_probe_substrate_of_enzyme_cyp2c191
midazolam_has_metabolite_1'-hydroxymidazolam1
midazolam_has_metabolite_4-hydroxymidazolam1
midazolam_in_vitro_probe_substrate_of_enzyme_cyp3a41
midazolam_primary_total_clearance_enzyme_cyp3a41
midazolam_substrate_of_cyp3a51
midodrine_bioavailability_continuous_value1
midodrine_has_metabolite_desglymidodrine1
mirtazapine_bioavailability_continuous_value1
mirtazapine_does_not_inhibit_cyp1a21
mirtazapine_does_not_inhibit_cyp2c191
mirtazapine_does_not_inhibit_cyp2c91
mirtazapine_does_not_inhibit_cyp2d61
mirtazapine_does_not_inhibit_cyp2e11
mirtazapine_fraction_absorbed_continuous_value1
mirtazapine_is_not_substrate_of_cyp2a61
mirtazapine_is_not_substrate_of_cyp2b61
mirtazapine_is_not_substrate_of_cyp2c191
mirtazapine_is_not_substrate_of_cyp2e11
mirtazapine_substrate_of_cyp3a51
modafinil-sulfone_inhibits_cyp2c191
modafinil_has_metabolite_modafinil-sulfone1
modafinil_inhibits_cyp2c191
modafinil_primary_total_clearance_mechanism_Metabolic_Clearance1
modafinil_substrate_of_cyp3a41
molindone_primary_total_clearance_mechanism_Metabolic_Clearance1
montelukast_does_not_inhibit_cyp2a61
montelukast_does_not_inhibit_cyp2c191
montelukast_does_not_inhibit_cyp2c81
montelukast_does_not_inhibit_cyp2d61
montelukast_does_not_inhibit_cyp3a41
montelukast_inhibition_constant_cyp2c81
nefazodone_does_not_inhibit_cyp1a21
nefazodone_in_viVo_selective_inhibitor_of_enzyme_cyp3a41
nefazodone_increases_auc_midazolam1
nefazodone_inhibits_cyp3a51
nefazodone_is_not_substrate_of_cyp1a21
nefazodone_is_not_substrate_of_cyp2c191
nefazodone_is_not_substrate_of_cyp2c81
nefazodone_is_not_substrate_of_cyp2c91
nefazodone_substrate_of_cyp3a41
nicardipine_bioavailability_continuous_value1
norfloxacin_inhibits_cyp1a21
norfluoxetine_inhibition_constant_cyp3a41
olanzapine_has_metabolite_10-N-glucuronide1
olanzapine_inhibition_constant_cyp2c191
olanzapine_inhibition_constant_cyp2c91
olanzapine_inhibition_constant_cyp3a41
olanzapine_maximum_concentration_continuous_value1
olanzapine_primary_total_clearance_mechanism_Metabolic_Clearance1
olanzapine_substrate_of_cyp2d61
omeprazole_does_not_inhibit_cyp2d61
omeprazole_in_vitro_probe_substrate_of_enzyme_cyp2c191
omeprazole_in_vitro_selective_inhibitor_of_enzyme_cyp2c191
omeprazole_increases_auc_escitalopram1
omeprazole_inhibits_cyp2c191
omeprazole_primary_total_clearance_enzyme_cyp2c191
p-nitrophenol_in_vitro_probe_substrate_of_enzyme_cyp2e11
paclitaxel_has_metabolite_6alpha-hydroxy-paclitaxel1
paclitaxel_in_vitro_probe_substrate_of_enzyme_cyp2c81
paliperidone_bioavailability_continuous_value1
paliperidone_does_not_inhibit_cyp2c191
paliperidone_does_not_inhibit_cyp2c81
paliperidone_does_not_inhibit_cyp2d61
paliperidone_does_not_inhibit_cyp2e11
paliperidone_does_not_inhibit_cyp3a41
paliperidone_does_not_inhibit_cyp3a51
paliperidone_inhibition_constant_cyp2d61
paliperidone_primary_total_clearance_mechanism_Renal_Excretion1
pantoprazole_bioavailability_continuous_value1
pantoprazole_does_not_inhibit_cyp2d61
pantoprazole_maximum_concentration_continuous_value1
pantoprazole_primary_total_clearance_enzyme_cyp2c191
pantoprazole_primary_total_clearance_mechanism_Metabolic_Clearance1
pantoprazole_substrate_of_cyp2c191
pantoprazole_substrate_of_cyp3a41
paroxetine_increases_auc_imipramine1
paroxetine_increases_auc_mirtazapine1
paroxetine_increases_auc_nortriptyline1
paroxetine_increases_auc_paliperidone1
paroxetine_increases_auc_risperidone1
paroxetine_permanently_deactivates_catalytic_function_cyp2d61
paroxetine_primary_total_clearance_mechanism_Metabolic_Clearance1
paroxetine_substrate_of_cyp2d61
perphenazine_does_not_inhibit_cyp2c191
perphenazine_has_metabolite_7-hydroxyperphenazine1
perphenazine_inhibition_constant_cyp1a21
perphenazine_inhibition_constant_cyp2d61
perphenazine_maximum_concentration_continuous_value1
perphenazine_primary_total_clearance_mechanism_Metabolic_Clearance1
perphenazine_substrate_of_cyp2c191
phenacetin_in_vitro_probe_substrate_of_enzyme_cyp1a21
pioglitazone_inhibition_constant_cyp2c81
prasugrel_increases_auc_bupropion1
pravastatin_does_not_inhibit_cyp2c81
pravastatin_has_metabolite_3alpha-hydroxypravastatin1
pravastatin_primary_total_clearance_mechanism_Renal_Excretion1
propafenone_inhibits_cyp1a21
propoxyphene_has_metabolite_norpropoxyphene1
quetiapine_does_not_inhibit_cyp1a21
quetiapine_does_not_inhibit_cyp2c191
quetiapine_does_not_inhibit_cyp2c91
quetiapine_does_not_inhibit_cyp2d61
quetiapine_does_not_inhibit_cyp3a41
quetiapine_has_metabolite_7-hydroxy-N-desalkyl-quetiapine1
quetiapine_has_metabolite_7-hydroxy-quetiapine1
quetiapine_has_metabolite_N-desalkylquetiapine1
quetiapine_has_metabolite_quetiapine-sulfoxide1
quetiapine_is_not_substrate_of_cyp1a21
quetiapine_is_not_substrate_of_cyp2c191
quetiapine_is_not_substrate_of_cyp2c91
quetiapine_is_not_substrate_of_cyp2e11
quetiapine_primary_total_clearance_mechanism_Metabolic_Clearance1
quinidine_in_viVo_selective_inhibitor_of_enzyme_cyp2d61
quinidine_in_vitro_selective_inhibitor_of_enzyme_cyp2d61
quinidine_increases_auc_venlafaxine1
quinidine_inhibits_cyp2d61
rabeprazole_bioavailability_continuous_value1
rabeprazole_primary_total_clearance_mechanism_Metabolic_Clearance1
rabeprazole_substrate_of_cyp2c191
rabeprazole_substrate_of_cyp3a51
ranolazine_inhibits_cyp2d61
ranolazine_inhibits_cyp3a41
ranolazine_inhibits_cyp3a51
ranolazine_maximum_concentration_continuous_value1
ranolazine_primary_total_clearance_enzyme_cyp3a41
ranolazine_primary_total_clearance_mechanism_Metabolic_Clearance1
ranolazine_substrate_of_cyp2d61
reduced-haloperidol_has_metabolite_4-(4-chlorophenyl)-4-hydroxypiperidine1
risperidone_does_not_inhibit_cyp2c191
risperidone_maximum_concentration_continuous_value1
risperidone_primary_metabolic_clearance_enzyme_cyp2d61
risperidone_primary_total_clearance_mechanism_Metabolic_Clearance1
risperidone_substrate_of_cyp3a41
ritonavir_increases_auc_trazodone1
ritonavir_inhibits_cyp3a51
rosiglitazone_does_not_inhibit_cyp1a11
rosiglitazone_does_not_inhibit_cyp1a21
rosiglitazone_does_not_inhibit_cyp2a61
rosiglitazone_does_not_inhibit_cyp2b61
rosiglitazone_does_not_inhibit_cyp2c191
rosiglitazone_does_not_inhibit_cyp2c81
rosiglitazone_does_not_inhibit_cyp2c91
rosiglitazone_does_not_inhibit_cyp2d61
rosiglitazone_does_not_inhibit_cyp2e11
rosiglitazone_does_not_inhibit_cyp3a41
rosiglitazone_does_not_inhibit_cyp3a51
rosiglitazone_inhibition_constant_cyp2c81
rosiglitazone_primary_total_clearance_enzyme_cyp2c81
rosuvastatin_does_not_inhibit_cyp2c81
rosuvastatin_fraction_absorbed_continuous_value1
rosuvastatin_has_metabolite_N-desmethylrosuvastatin1
rosuvastatin_is_not_substrate_of_cyp3a41
rosuvastatin_maximum_concentration_continuous_value1
rosuvastatin_primary_metabolic_clearance_enzyme_cyp2c91
rosuvastatin_primary_total_clearance_mechanism_Biliary_Excretion1
sertraline_has_metabolite_N-desmethylsertraline1
sertraline_substrate_of_cyp2c191
sildenafil_primary_total_clearance_enzyme_cyp3a41
simvastatin_does_not_inhibit_cyp3a41
simvastatin_has_metabolite_beta-hydroxy-simvastatin1
simvastatin_inhibition_constant_cyp2c81
simvastatin_primary_total_clearance_enzyme_cyp3a41
simvastatin_primary_total_clearance_mechanism_Metabolic_Clearance1
sulfinpyrazone_in_vitro_selective_inhibitor_of_enzyme_cyp2c91
sulphaphenazole_in_vitro_selective_inhibitor_of_enzyme_cyp2c91
tamoxifen_has_metabolite_4-hydroxytamoxifin1
tamoxifen_has_metabolite_N-desmethyltamoxifen1
tamoxifen_primary_total_clearance_mechanism_Metabolic_Clearance1
tamoxifen_substrate_of_cyp2c91
tamoxifen_substrate_of_cyp2d61
tamoxifen_substrate_of_cyp3a41
tamoxifen_substrate_of_cyp3a51
telithromycin_inhibits_cyp3a51
terbinafine_increases_auc_paroxetine1
terbinafine_increases_auc_venlafaxine1
teriflunomide_inhibits_cyp2c91
testosterone_in_vitro_probe_substrate_of_enzyme_cyp3a41
theophylline_has_metabolite_1,3-dimethyluric-acid1
theophylline_has_metabolite_1-methylxanthine1
theophylline_has_metabolite_3-methylxanthine1
theophylline_has_metabolite_caffeine1
theophylline_in_vitro_probe_substrate_of_enzyme_cyp1a21
theophylline_primary_total_clearance_enzyme_cyp1a21
theophylline_primary_total_clearance_mechanism_Metabolic_Clearance1
thioridazine_does_not_inhibit_cyp2c191
thioridazine_has_metabolite_sulforidazine1
thioridazine_has_metabolite_thioridazine-5-sulfoxide1
thioridazine_inhibition_constant_cyp2d61
thioridazine_primary_total_clearance_enzyme_cyp2d61
thiothixene_does_not_inhibit_cyp2c191
thiothixene_inhibition_constant_cyp2d61
threohydrobupropion_maximum_concentration_continuous_value1
threohydrobupropion_primary_total_clearance_mechanism_Renal_Excretion1
ticlopidine_increases_auc_bupropion1
ticlopidine_inhibition_constant_cyp2b61
ticlopidine_inhibition_constant_cyp2c191
tolbutamide_in_vitro_probe_substrate_of_enzyme_cyp2c91
tolbutamide_primary_total_clearance_enzyme_cyp2c91
topiramate_does_not_inhibit_cyp2b61
topiramate_does_not_inhibit_cyp2c191
topiramate_does_not_inhibit_cyp2d61
topiramate_does_not_inhibit_cyp3a51
topiramate_primary_total_clearance_mechanism_Renal_Excretion1
trazodone_has_metabolite_M-chlorophenylpiperazine1
trazodone_maximum_concentration_continuous_value1
trazodone_substrate_of_cyp3a41
triazolam_in_vitro_probe_substrate_of_enzyme_cyp3a41
triazolam_primary_total_clearance_enzyme_cyp3a41
trimethoprim_inhibits_cyp2c81
troleandomycin_in_vitro_selective_inhibitor_of_enzyme_cyp3a41
valproate_increases_auc_hydroxybupropion1
valproate_primary_total_clearance_mechanism_Metabolic_Clearance1
venlafaxine_fraction_absorbed_continuous_value1
venlafaxine_increases_auc_desipramine1
venlafaxine_increases_auc_haloperidol1
venlafaxine_increases_auc_imipramine1
venlafaxine_increases_auc_risperidone1
venlafaxine_inhibits_cyp2d61
venlafaxine_primary_total_clearance_enzyme_cyp2d61
venlafaxine_primary_total_clearance_mechanism_Metabolic_Clearance1
venlafaxine_substrate_of_cyp3a41
verapamil_increases_auc_imipramine1
verapamil_increases_auc_risperidone1
verapamil_inhibits_cyp1a21
verapamil_inhibits_cyp3a41
verapamil_inhibits_cyp3a51
voriconazole-N-oxide_inhibits_cyp2c191
voriconazole-N-oxide_inhibits_cyp2c91
voriconazole-N-oxide_inhibits_cyp3a41
voriconazole_bioavailability_continuous_value1
voriconazole_has_metabolite_voriconazole-N-oxide1
voriconazole_inhibits_cyp2c191
voriconazole_inhibits_cyp2c91
voriconazole_inhibits_cyp3a41
voriconazole_primary_total_clearance_enzyme_cyp2c191
voriconazole_primary_total_clearance_mechanism_Metabolic_Clearance1
voriconazole_substrate_of_cyp2c191
voriconazole_substrate_of_cyp2c91
voriconazole_substrate_of_cyp3a41
warfarin_primary_total_clearance_enzyme_cyp2c91
zafirlukast_inhibits_cyp3a41
zafirlukast_maximum_concentration_continuous_value1
zafirlukast_substrate_of_cyp2c91
zaleplon_bioavailability_continuous_value1
zaleplon_is_not_substrate_of_cyp2d61
zaleplon_primary_total_clearance_mechanism_Metabolic_Clearance1
zaleplon_substrate_of_cyp3a41
ziprasidone_does_not_inhibit_cyp3a41
ziprasidone_has_metabolite_S-methyl-dihydroziprasidone1
ziprasidone_has_metabolite_benzisothiazole-sulphone1
ziprasidone_has_metabolite_benzisothiazole-sulphoxide1
ziprasidone_inhibition_constant_cyp2d61
ziprasidone_is_not_substrate_of_cyp2c191
ziprasidone_is_not_substrate_of_cyp2c91
ziprasidone_is_not_substrate_of_cyp2d61
ziprasidone_primary_total_clearance_mechanism_Metabolic_Clearance1
ziprasidone_substrate_of_cyp1a21
zolpidem_maximum_concentration_continuous_value1
zolpidem_substrate_of_cyp3a51